Soros Fund Management LLC Grows Holdings in Evolus, Inc. (NASDAQ:EOLS)

Soros Fund Management LLC lifted its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 29.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,100,000 shares of the company's stock after acquiring an additional 250,000 shares during the period. Soros Fund Management LLC owned 1.74% of Evolus worth $12,144,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Schonfeld Strategic Advisors LLC lifted its position in Evolus by 62.6% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 34,700 shares of the company's stock valued at $383,000 after buying an additional 13,363 shares during the period. Nantahala Capital Management LLC boosted its stake in Evolus by 10.8% during the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock worth $34,557,000 after acquiring an additional 305,300 shares in the last quarter. Northern Trust Corp grew its holdings in Evolus by 9.3% in the fourth quarter. Northern Trust Corp now owns 531,167 shares of the company's stock worth $5,864,000 after purchasing an additional 45,384 shares during the period. Tri Locum Partners LP purchased a new position in shares of Evolus during the fourth quarter valued at approximately $8,198,000. Finally, Boothbay Fund Management LLC boosted its position in shares of Evolus by 30.9% in the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company's stock worth $14,217,000 after purchasing an additional 304,065 shares in the last quarter. Hedge funds and other institutional investors own 90.69% of the company's stock.

Evolus Price Performance

EOLS stock traded up $0.28 during mid-day trading on Friday, hitting $12.08. The company had a trading volume of 957,476 shares, compared to its average volume of 664,883. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The company has a market capitalization of $778.81 million, a price-to-earnings ratio of -13.27 and a beta of 1.11. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82. The company has a 50-day moving average price of $11.98 and a 200 day moving average price of $12.74.

Insiders Place Their Bets

In related news, insider Rui Avelar sold 27,904 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the sale, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Moatazedi sold 6,251 shares of the stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the transaction, the insider now owns 508,619 shares of the company's stock, valued at $6,306,875.60. This trade represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 60,575 shares of company stock valued at $794,369 in the last quarter. 6.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Evolus in a research report on Wednesday, April 9th. Barclays upped their price objective on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research began coverage on shares of Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of Evolus in a research note on Thursday, April 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.